Immunogenicity and efficacy of highly purified invasin complex vaccine from Shigella flexneri 2a

Vaccine

Volumn 26, Issue 10, 2008, Pages 1353-1364

  Turbyfill, K Ross ^a   Kaminski, Robert W ^a   Oaks, Edwin V ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Invasin complex; IpaB; IpaC; LPS; Shigella vaccine

Indexed keywords

INVAPLEX; SHIGELLA VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; GEL PERMEATION CHROMATOGRAPHY; GUINEA PIG; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHIGELLA FLEXNERI;

ADHESINS, BACTERIAL; ANIMALS; BLOTTING, WESTERN; CHROMATOGRAPHY, GEL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GUINEA PIGS; IMMUNOASSAY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; KERATOCONJUNCTIVITIS; LIPOPOLYSACCHARIDES; MOLECULAR WEIGHT; SHIGELLA FLEXNERI; SHIGELLA VACCINES;

EID: 39249084015     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.12.040     Document Type: Article

References (32)

1. Li A., Rong Z.C., Ekwall E., Forsum U., and Lindberg A.A. Serum antibody responses against Shigella lipopolysaccharides and invasion plasmid-coded antigens in Shigella infected Swedish patients. Scand J Infect Dis 25 (1993) 569-577
2. Oaks E.V., Hale T.L., and Formal S.B. Serum immune response to Shigella protein antigens in Rhesus monkeys and humans infected with Shigella spp. Infect Immun 53 1 (1986) 57-63
3. Sandlin R.C., Goldberg M.B., and Maurelli A.T. Effect of O side-chain length and composition on the virulence of Shigella flexneri 2a. Mol Microbiol 22 (1996) 63-73
4. West N.P., Sansonetti P., Mounier J., Exley R.M., Parsot C., Guadagnini S., et al. Optimization of virulence functions through glucosylation of Shigella LPS. Science 307 5713 (2005) 1313-1317
5. Turbyfill K.R., Hartman A.B., and Oaks E.V. Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine. Infect Immun 68 (2000) 6624-6632
6. Kaminski R.W. Immunological and functional characterization of a novel mucosal adjuvant isolated from Shigella spp. [Doctoral] (2004), George Mason University, Fairfax, VA
7. Payne S.M., and Finkelstein R.A. Detection and differentiation of iron-responsive avirulent mutants on Congo red agar. Infect Immun 18 1 (1977) 94-98
8. Mills J.A., Buysse J.M., and Oaks E.V. Shigella flexneri invasion plasmid antigens B and C: epitope location and characterization with monoclonal antibodies. Infect Immun 56 11 (1988) 2933-2941
9. Davis R., Marquart M.E., Lucius D., and Picking W.D. Protein-protein interactions in the assembly of Shigella flexneri invasion plasmid antigens IpaB and IpaC into protein complexes. Biochem Biophys Acta 1429 (1998) 45-56
10. Picking W.L., Mertz J.A., Marquart M.E., Picking W.D., and Cloning. expression, and affinity purification of recombinant Shigella flexneri invasion plasmid antigens IpaB and IpaC. Protein Expr Purif 8 (1996) 401-408
11. Westphal O., and Jann K. Bacterial Lipopolysaccharides. Extraction with phenol water and further applications of the procedure. Methods Carbohydr Chem 5 (1965) 83-91
12. Mallett C.P., VanDeVerg L., Collins H.H., and Hale T.L. Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model. Vaccine 11 (1993) 190-196
13. Hartman A.B., Powell C.J., Shulta C.L., Oaks E.V., and Eckels K.H. Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains. Infect Immun 59 11 (1991) 4075-4083
14. Hartman A.B., Verg L.L.V.D., Mainhart C.R., Tall B.D., and Smith-Gill S.J. Specificity of monoclonal antibodies elicited by mucosal infection of BALB/c mice with virulent Shigella flexneri 2a. Clin Diag Lab Immunol 3 (1996) 584-589
15. Turbyfill K.R., Mertz J.A., Mallett C.P., and Oaks E.V. Identification of epitope and surface-exposed domains of Shigella flexneri invasion plasmid antigen D (IpaD). Infect Immun 66 (1998) 1999-2006
16. Oaks E.V., and Turbyfill K.R. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine. Vaccine 24 (2006) 2290-2301
17. Blocker A., Gounon P., Larquet E., Niebuhr K., Cabiaux V., Parsot C., et al. The tripartite type III secreton of Shigella flexneri inserts IpaB and IpaC into host-membranes. J Cell Biol 147 (1999) 683-693
18. Menard R., Prevost M.-C., Gounon P., Sansonetti P., and Dehio C. The secreted Ipa complex of Shigella flexneri promotes entry into mammalian cells. Proc Natl Acad Sci USA 93 (1996) 1254-1258
19. Page A., Ohayon H., Sansonetti P.J., and Parsot C. The secreted IpaB and IpaC invasins and their cytoplasmic chaperone IpgC are required for intercellular dissemination of Shigella flexneri. Cell Microbiol 1 (1999) 183-193
20. Espina M., Olive A.J., Kenjale R., Moore D.S., Ausar S.F., Kaminski R.W., et al. IpaD localizes to the tip of the type III secretion system needle of Shigella flexneri. Infect Immun 74 8 (2006) 4391-4400
21. Mallett C.P., Hale T.L., Kaminski R.W., Larsen T., Orr N., Cohen D., et al. Intranasal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection. Infect Immun 63 (1995) 2382-2386
22. Fries L.F., Montemarano A.D., Mallett C.P., Taylor D.N., Hale T.L., and Lowell G.H. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect Immun 69 (2001) 4545-4553
23. Orr N., Robin G., Cohen D., Arnon R., and Lowell G.H. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infect Immun 61 6 (1993) 2390-2395
24. Tran N., Serfis A.B., Osiecki J.C., Picking W.L., Coye L., Davis R., et al. Interaction of Shigella flexneri IpaC with model membranes correlates with effects on cultured cells. Infect Immun 68 6 (2000) 3710-3715
25. Hayward R.D., McGhie E.J., and Koronakis V. Membrane fusion activity of purified SipB, a Salmonella surface protein essential for mammalian cell invasion. Mol Microbiol 37 4 (2000) 727-739
26. Hume P.J., McGhie E.J., Hayward R.D., and Koronakis V. The purified Shigella IpaB and Salmonella SipB translocators share biochemical properties and membrane topology. Mol Microbiol 49 (2003) 425-439
27. Menard R., Sansonetti P., and Parsot C. The secretion of the Shigella flexneri Ipa invasins is activated by epithelial cells and controlled by IpaB and IpaD. EMBO J 13 22 (1994) 5293-5302
28. Saunders N.B., Shoemaker D.R., Brandt B.L., Moran E.E., Larsen T., and Zollinger W.D. Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice. Infect Immun 67 1 (1999) 113-119
29. Zollinger W.D., Kasper D.L., Veltri B.J., and Artenstein M.S. Isolation and characterization of a native cell wall complex from Neisseria meningitidis. Infect Immun 6 5 (1972) 835-851
30. Kadurugamuwa J.L., and Beveridge T.J. Delivery of the non-membrane-permeative antibiotic gentamicin into mammalian cells by using Shigella flexneri membrane vesicles. Antimicrob Agents Chemother 42 (1998) 1476-1483
31. Kadurugamuwa J.L., and Beveridge T.J. Membrane vesicles derived from Pseudomonas aeruginosa and Shigella flexneri can be integrated into the surfaces of other Gram-negative bacteria. Microbiology 145 (1999) 2051-2060
32. Suzuki T., Yoshikawa Y., Ashida H., Iwai H., Toyotome T., Matsui H., et al. High vaccine efficacy against shigellosis of recombinant noninvasive Shigella mutant that expresses Yersinia invasin. J Immunol 177 7 (2006) 4709-4717